Analysts at StockNews.com assumed coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Get Rating) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Merrimack Pharmaceuticals stock opened at $6.24 on Wednesday. The company has a market capitalization of $83.68 million, a PE ratio of -44.57 and a beta of 1.69. The firm has a fifty day simple moving average of $5.49 and a two-hundred day simple moving average of $5.40. Merrimack Pharmaceuticals has a twelve month low of $3.66 and a twelve month high of $7.41.
A number of hedge funds have recently added to or reduced their stakes in MACK. Morgan Stanley raised its stake in Merrimack Pharmaceuticals by 87.8% in the second quarter. Morgan Stanley now owns 11,161 shares of the biopharmaceutical company’s stock worth $72,000 after buying an additional 5,218 shares in the last quarter. BlackRock Inc. raised its stake in Merrimack Pharmaceuticals by 12.8% in the third quarter. BlackRock Inc. now owns 211,051 shares of the biopharmaceutical company’s stock worth $1,020,000 after buying an additional 23,961 shares in the last quarter. Citadel Advisors LLC grew its holdings in Merrimack Pharmaceuticals by 38.8% in the third quarter. Citadel Advisors LLC now owns 10,622 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 2,970 shares during the period. Radnor Capital Management LLC purchased a new stake in Merrimack Pharmaceuticals in the fourth quarter worth about $52,000. Finally, Yakira Capital Management Inc. grew its holdings in Merrimack Pharmaceuticals by 21.1% in the fourth quarter. Yakira Capital Management Inc. now owns 73,450 shares of the biopharmaceutical company’s stock worth $287,000 after purchasing an additional 12,816 shares during the period. 55.93% of the stock is owned by institutional investors.
Merrimack Pharmaceuticals Company Profile (Get Rating)
Merrimack Pharmaceuticals, Inc operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
- Get a free copy of the StockNews.com research report on Merrimack Pharmaceuticals (MACK)
- This Still Isn’t A Buyable Bottom For Stocks
- ABM Industries, A Clean Play For Dirty Economic Times
- Should Silver Stocks Be A Part Of Your Portfolio?
- Dividend-Paying Midstream Oil Companies That Could Help You The Mitigate Market Volatility
- Don’t Get Too Bullish On Lennar Even Though It’s A Good Buy
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.